Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UNI91103 Intranasal Spray in Asymptomatic or Mild COVID-19
NCT04932915Phase 2Terminated
- Sponsor
- UNION therapeutics
- Start
- Sep 2021
- Primary completion
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing UNI91103 with Placebo (2 arms). Primary endpoint: Proportion of subjects with worsened symptoms any time from Day 3 to Day 10 compared with baseline. Started Sep 2021; status: terminated.
02
Drugs
niclosamide
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04932915.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04932915.